Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients

Crescenzo D’Alterio 1,†, Anna Spina 1,†, Laura Arenare 2, Paolo Chiodini 3,*, Maria Napolitano 1, Francesca Galdiero 1, Luigi Portella 1, Vittorio Simeon 3,*, Simona Signoriello 3,*, Francesco Raspagliesi 4, Domenica Lorusso 5,6, Carmela Pisano 7, Nicoletta Colombo 9, Gian Franco Zannoni 9,10,‡, Nunzia Simona Losito 11, Rossella De Cecio 11, Giosuè Scognamiglio 11,*, Daniela Califano 1,*, Daniela Russo 1,*, Valentina Tuninetti 12,*, Maria Carmela Piccirillo 2,*, Piera Gargiulo 2, Francesco Perrone 2,*, Sandro Pignata 7,‡ and Stefania Scala 1,*,+,

Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori IRCCS—Fondazione G. Pascale, 80131 Napoli, Italy; c.dalterio@istitutotumori.na.it (C.D.); a.spina@istitutotumori.na.it (A.S.); m.napolitano@istitutotumori.na.it (M.N.); f.galdiero@istitutotumori.na.it (F.G.); l.portella@istitutotumori.na.it (L.P.); d.califano@istitutotumori.na.it (D.C.); d.russo@istitutotumori.na.it (D.R.)

1 Clinical Trials Unit, Istituto Nazionale Tumori IRCCS—Fondazione G. Pascale, 80131 Napoli, Italy; larenare@istitutotumori.na.it (L.A.); m.piccirillo@istitutotumori.na.it (M.P.); piera.gargiulo@istitutotumori.na.it (P.G.); f.perrone@istitutotumori.na.it (F.P.)

2 Section of Statistics, Department of Mental Health and Public Medicine, Università degli Studi della Campania Luigi Vanvitelli, 80138 Napoli, Italy; paolo.chiodini@unicampania.it (P.C.); vittorio.simeon@unicampania.it (V.S.); simona.signoriello@unicampania.it (S.S.)

3 Gynecological Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy; francesco.raspagliesi@istitutotumori.mi.it

4 Division of Gynecologic Oncology, Department of Women and Child Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy; dominenca.lorusso@policlinicogemelli.it

5 Department of Life Science and Public Health, Catholic University of Sacred Heart, Largo Agostino Gemelli, 00168 Rome, Italy

6 Urogynaecological Medical Oncology, Istituto Nazionale Tumori IRCCS—Fondazione G. Pascale, 80131 Napoli, Italy; c.pisano@istitutotumori.na.it (C.P.); s.pignata@istitutotumori.na.it (S.P.)

7 Gynecologic Cancer Program, Università degli Studi di Milano-Bicocca, 20163 Milan, Italy; nicoletta.colombo@unimib.it

8 Gynecopathology and Breast Pathology Unit, Department of Woman, Child and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy; gianfranco.zannoni@unicatt.it

9 Pathological Anatomy Institute, Catholic University of Sacred Hearth, 00168 Rome, Italy

10 Pathology Unit, Istituto Nazionale Tumori IRCCS—Fondazione G. Pascale, 80131 Napoli, Italy; n.losito@istitutotumori.na.it (N.S.L.); r.dececi@istitutotumori.na.it (R.D.C.); giosu.seognamiglio@istitutotumori.mi.it (G.S.)

11 FPO IRCCS Istituto di Candiolo, 10060 Turin, Italy; valentina.tuninetti@ircc.it

* These authors contributed equally to this work.
† These authors contributed equally to this work.
‡ These authors contributed equally to this work.
+ These authors contributed equally to this work.

Abstract: This study investigated the prognostic role of the CXCR4-CXCL12-CXCR7 axis in advanced epithelial ovarian cancer (EOC) patients receiving first-line treatment within the MITO16A/MaNGO-OV2 phase-IV trial. CXCR4-CXCL12-CXCR7 expression was evaluated in the epithelial and stromal component of 308 EOC IHC-stained tumor samples. The statistical analysis focused on biomarkers’ expression, their association with other variables and prognostic value. Zero-inflated tests, shrinkage, bootstrap procedures, and multivariable models were applied. The majority of EOC (75.0%) expressed CXCR4 and CXCR7, 56.5% expressed the entire CXCR4-CXCL12-CXCR7 axis, while only 4.6% were
negative for CXCL12 and its cognate receptors, in regard to the epithelial component. Stromal CXCL12 and CXCR7, expressed in 11.2% and 65.5%, respectively, were associated with the FIGO stage. High CXCL12 in epithelial cancer cells was associated with shorter progression-free and overall survival. However, after adjusting for overfitting due to best cut-off multiplicity testing, the significance was lost. This is a wide-ranging, prospective study in which CXCR4-CXCL12-CXCR7 were systematically evaluated in epithelial and stromal components, in selected stage III-IV EOC. Although CXCL12 was not prognostic, epithelial expression identified high-risk FIGO stage III patients for PFS. These data suggest that it might be worth studying the CXCL12 axis as a therapeutic target to improve treatment efficacy in EOC patients.

**Keywords:** chemokine; CXCR4-CXCL12-CXCR7 axis; ovarian cancer; prognosis; tumor microenvironment

1. **Introduction**

Epithelial ovarian cancer (EOC) accounts for approximately 90% of ovarian cancers [1]. The majority (60%) are high-grade serous carcinomas (HGSCs), followed by endometrial, clear cell, mucinous, and low-grade serous carcinomas [2]. Cytoreductive (debulking) surgery and platinum/paclitaxel chemotherapy are the standard therapeutic approaches [1]. While stage I and II EOC patients have a 76–91% 5-year survival rate [3], only 30% of patients with advanced-stage disease survive more than 5 years [1]. Poor prognosis depends on late diagnosis, acquired resistance to platinum-based regimen [4] and recurrence [5]. The anti-VEGF antibody, bevacizumab, prolongs progression-free survival (PFS) in newly diagnosed and relapsed EOCs, and in combination with carboplatin plus paclitaxel is used for maintenance in first-line therapy [6]. Recently, poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors were introduced into the treatment of first-line and relapsed ovarian cancer [7,8]. Thus, it is crucial to identify the biological features to allow for patient characterization and the optimal therapeutic approach [9].

CXCR4 is a chemokine receptor that induces cell chemotaxis following a CXCL12 gradient [10]. CXCR4 participates in the EOC development [11], is expressed by ovarian cancer, tumor and stromal cells (myeloid or T cells), and cooperates with angiogenic factors to generate new vessels [12]. Silencing CXCR4 in human ovarian cancer cells reduces cell proliferation, migration and invasion and significantly decreases in vivo tumor development [11,13]. The only FDA-approved CXCR4 antagonist, AMD3100, sensitizes ovarian cancer to chemotherapy [14] and impairs the epithelial–mesenchymal transition (EMT) when coupled with paclitaxel (PTX)-loaded bovine serum albumin (BSA) nanoparticles [15,16]. CXCR4 further plays a role in cisplatin-resistance inducing let-7a, which suppresses the pro-apoptotic BCL-XL/S [17]. CXCL12 is present in 95% of ovarian cancer ascites, while CXCR4 is the only chemokine receptor expressed in ovarian cancer cells [18]. VEGF and CXCL12 cooperate to induce potent neovascularization, as VEGF up-regulates CXCR4 on vascular endothelial cells and synergize CXCL12-mediated vascular endothelial cells migration [19] through matrix metalloproteinases (MMPs) [20], while CXCR4 is overexpressed in high-grade serous carcinomas [12] and correlates with stage and metastasis development [10,21]. CXCL12 is an independent predictor of poor survival in ovarian cancer [22]. CXCR7/ACKR3 is the second CXCL12 receptor, and is also activated by interferon-inducible T-cell alpha chemoattractant I-TAC (CXCL11) [23]. The role of CXCR7 in EOC is poorly characterized, although the ligands, CXCL11 and CXCL12, are overexpressed in ovarian carcinomas [16,24]. In this study, we evaluated the epithelial and stromal cellular expression of CXCR4-CXCL12-CXCR7 in tumors from advanced ovarian cancer patients enrolled in the MITO16A/MaNGO-OV2 trial [25]. The MITO16A trial is a multicenter, phase IV, single arm trial. The aim of the trial was to explore the clinical and biological prognostic factors for advanced ovarian cancer patients receiving first-line treatment with carboplatin, paclitaxel, and bevacizumab, Patients with advanced (stage IIIB-IV) or recurrent, previously untreated, ovarian cancer received carboplatin, paclitaxel
plus bevacizumab for six 3-weekly cycles followed by bevacizumab single agent until progression or unacceptable toxicity up to a maximum of 22 total cycles. Both progression-free and overall survival were used as endpoints. After a median follow-up of 32.3 months (IQR 24.1–40.4), the median progression-free survival was 20.8 months (95% CI 19.1 to 22.0) and median overall survival was 41.1 months (95% CI 39.1 to 43.5). Performance status, stage, and residual disease after primary surgery were the most important clinical prognostic factors [25]; in this context, the prognostic role of epithelial and stromal expression of CXCR4-CXCL12-CXCR7 was evaluated.

2. Materials and Methods

2.1. Description of the Study

The MITO16A/MaNGO-OV2 (www.clinicaltrials.gov (accessed on 31 March 2022) number: NCT01706120 or EudraCT number: 2012-003043-29, hereafter indicated as MITO16A) is a single arm, multicenter, open-label, non-comparative, phase IV trial of first-line chemotherapy (carboplatin plus paclitaxel) plus bevacizumab, followed by bevacizumab as single agent until progression or up to 22 total cycles. Overall, 398 patients were prospectively enrolled from 47 participant centers. Twelve research groups designed the trial as an exploratory study and no a priori hypothesis was defined to calculate the sample size of the trial. The primary aim of the MITO16A was to study clinical and biological factors for their value as prognostic factors for progression-free or overall survival among patients receiving chemotherapy and bevacizumab as a first-line treatment.

The MITO16A was to study clinical and biological factors for their value as prognostic factors for progression-free or overall survival among patients receiving chemotherapy and bevacizumab as a first-line treatment.

Data were collected through https://usc-intnapoli.net (accessed on 31 March 2022) website. All participants signed an informed consent for both the clinical and translational part before entering the study.

2.2. Sample Collection and Review

Formalin-fixed, paraffin-embedded (FFPE) tumor blocks were collected and stored according to Italian guidelines [26] and pathological revision was performed at the Instituto Nazionale Tumori of Naples IRCCS “G. Pascale” as previously reported [27].

2.3. Preparation of Tissue Microarray

Using the most representative areas (at least 50% of cancer cells without necrosis) from each FFPE sample, a tissue microarray (TMA) was built. Three cores (1 mm) were collected from each of the eligible tumor blocks of 311 patients and arrayed into a recipient paraffin block (35 mm × 20 mm) using a semiautomatic tissue array instrument (Galileo CK3500 TMA, ISENET, Milan, Italy). Eventually, 7 TMA blocks were built and cut into 4 µm thick sections. The sample adequacy was evaluated.

2.4. Immunohistochemistry (IHC)

TMA sections were deparaffinized and rehydrated. Antigen retrieval was achieved in 10 mM sodium citrate buffer at pH 6.0, using microwave for 3 cycles of 10 min at 1-fold 2 min at 600 W and 2-fold 4 min at 360 W each. Slides were treated with 3% hydrogen peroxide for 10 min at 24 °C to stop endogenous peroxidase, and then blocked in biotin/avidin solution for 10 min. Immunostaining was performed by incubating with anti-CXCR4 (1:100, MAB172, R&D systems) or anti-CXCR7 (1:70, MAB42273, R&D systems) or anti-CXCL12 (1:50, MAB350, R&D systems) at 4 °C overnight. Anti-mouse secondary antibodies and peroxidase-labeled streptavidin were used (Dako, Carpinteria, California, CA, USA); diaminobenzidine reagent was employed to detect signals. The staining intensity was scored as 0 (negative), 1 (weak), 2 (moderate), or 3 (strong). The percentage of cells stained was counted. The H-Score was calculated [22]. The markers’ expression was separately evaluated on epithelial ovarian cancer cells and stromal cells within each TMA core.
2.5. Statistical Analyses

Data were described using the mean and standard deviation (SD) or median and interquartile range (IQR) for quantitative variables, and absolute and relative frequency for categorical variables. Each single biomarker was graphically described by histogram, evaluating its distribution and highlighting the presence of high-frequencies of 0 values. The correlation between biomarkers was investigated graphically by scatterplot and by a modified version of the Kendall test for zero-inflated values [28]. The association of each biomarker with the clinical prognostic factors was assessed using the Wilcoxon rank test for zero-inflated data (ZIW) for dichotomous variables and the Kruskal–Wallis test for zero-inflated data (ZIKW) for categorical variables, both with the use of a permutation test. Within each box plot, a circle was added at the bottom and its size was proportional to the percentage of 0 values. The prognostic effect of the clinical characteristics and biomarkers was tested considering progression-free survival (PFS) and overall survival (OS) as endpoints. PFS was defined as the time elapsing from inclusion in the study to the first occurrence of disease progression or death from any cause. OS was defined as the time elapsing from inclusion in the study and death from any cause.

To adjust the biomarker analyses, a prognostic model that included only clinical covariates was developed that was consistent with previously reported analyses (24). The model included: age (as category <65 vs. ≥65), ECOG performance status (PS 0 vs. PS 1–2), residual disease (none; ≤1 cm; >1 cm; not operated), FIGO stage (III vs. IV) and tumor histology (high-grade serous vs. other).

For each biomarker, tumor and stromal expression were paired and studied using univariate and multivariable analyses. First, for each biomarker, a model was estimated with the H-index of epithelial and stromal cells as a continuous variable after testing the linearity assumption using fractional polynomial and a dummy variable to account for 0 value. The interaction between tumor and stromal biomarker expression was also tested within this model. Second, the best cut-off value for each biomarker component (tumor or stroma) was defined as the one that minimizes the $p$-value of HR in a model adjusted for the other component (tumor or stroma); the best cut-off search was calculated on PFS (considered as the most sensitive end-point due to a higher number of events) and then applied to the OS. The OS and PFS curves for each biomarker category according to the identified cut-offs were estimated with the Kaplan–Meier method, and compared with a two-sided log-rank test.

Third, in the multivariable analyses with the Cox proportional hazard model, the prognostic value of each biomarker pair (both as continuous and as categorical according to the previously calculated cut-off) was adjusted for the clinical characteristics (see above) and reported as hazard ratios (HRs) and 95% confidence intervals (CIs).

To adjust for overfitting, HR estimates of best cut-off categories were calculated using a shrinkage procedure with the 95% CI calculated with a bootstrap percentile method [29].

Finally, in order to generate new biological–clinical hypotheses, exploratory analyses were performed to estimate the effect of biomarker best cut-off categories for predefined subgroups of patients, defined by categories of clinical variables (tumor histology, FIGO stage and residual disease), by means of the Cox regression model and the heterogeneity of the effect was measured by the interaction test. Such analyses were only conducted with PFS as the clinical outcome because of the higher number of events.

Data were analyzed using R software version 3.6.0 (R Foundation for Statistical Computing, Vienna, Austria).

3. Results

3.1. Patients Clinical and Pathological Data

Out of 398 patients enrolled in the MITO16A study, samples were available for 308 (77%) patients. Tumor blocks from thirteen patients were not available, sixty-two samples had insufficient amounts of tumor tissue and were considered inadequate for the tissue microarray (TMA). A further 12 samples were excluded because they were collected af-
ter neoadjuvant chemotherapy. Out of 311 patients used for the TMA, 3 patients were excluded due to technical issues. Finally, 308 patients were fully characterized and the data were available for statistical analysis (Supplementary Materials, Figure S1). Among the 308 patients, the median age was 58.8 years (range 49.8–65.9), with n = 88 patients (28.6%) ≥65 years old (the other age classes were 18–30: 1 (0.3%); 30–45: 31 (10.1%); 45–65: 188 (61.0%)). At diagnosis, the majority of patients had a good performance status score of PS ECOG 0 (80.2%) and FIGO stage IIIC (71.1%). According to the central histological revision, high-grade serous carcinoma (HGSC) was the most common histological type (85.7%). Patient characteristics are reported in Supplementary Materials, Table S1. The clinical prognostic factors were reported in Supplementary Materials, Table S2.

3.2. CXCR4-CXCL12-CXCR7 Axis Is Highly Expressed in Advanced EOC

CXCR4-CXCL12-CXCR7 expression was evaluated for the epithelial and stromal component in 308 EOC samples through IHC. CXCR4 staining was cytoplasmic, perinuclear and nuclear in both epithelial and stromal cells (Figure 1A,B).

![Figure 1](image-url)  
**Figure 1.** CXCR4-CXCL12-CXCR7 axis is expressed in epithelial and stroma in advanced EOC. CXCR4-CXCL12-CXCR7 expression in epithelial (A,C,E) and stromal cells (B,D,F) for low (upper panel) and high H-score (lower panel) expression based on best cut-off value for each biomarker component (tumor or stroma) (400× magnification; bars 50 µm).

The median CXCR4 H-score was 63.3 (interquartile range (IQR) 30.0–93.3) in epithelial and 20.0 (IQR 0.0–46.7) in stromal cells (Figure 2A). CXCL12 staining was observed in cell membranes and cytoplasm; in particular, CXCL12 showed predominantly diffuse strong epithelial membrane positivity (Figure 1C,D). The median H-index of CXCL12 was 20.0 (IQR 0.0–70.0) in epithelial cells and 0 in stromal cells, with few positive cases (11.5%) (Figure 2A).

The CXCR7 expression was mainly cytoplasmic and heterogeneous (Figure 1E,F). The median CXCR7 expression was 33.3 (IQR 10.0–70.0) in epithelial and 16.7 (IQR 0.0–43.3) in stromal cells (Figure 2A). In addition, 56.5% of the EOCs expressed the entire axis CXCR4-CXCL12-CXCR7, while only 4.5% were negative for both CXCL12 and its cognate receptors (Table 1). The majority of stromal infiltrating cells express CXCR4 and CXCR7 (40.6%) receptors (Table 1).

The correlations among the markers were weak, suggesting that CXCR4, CXCL12 and CXCR7 expression is independent in EOC (Supplementary Materials, Figure S2). Stromal CXCR7 and CXCL12 were significantly associated with FIGO stage (p = 0.007 and 0.033, respectively). In particular, stromal CXCR7 and CXCL12 were significantly lower in FIGO stage IV (Figure 2B).
Figure 2. Decrease in stromal CXCR7 and CXCL12 in FIGO stage IV. Relative distribution of CXCR4-CXCL12-CXCR7 in EOC epithelial and stroma (A). CXCR4-CXCL12-CXCR7 percentage in epithelial and stromal cells (% of epithelial) in each H-score interval (X axes). Y axes showed the % of individuals with a given interval of CXCR4-CXCL12-CXCR7 expression. The median with interquartile range (IQR) was also reported, as a measure of central tendency for a skewed dataset. Box whisker plots showed the association between FIGO stage (stage III vs. IV) and CXCR4- CXCL12-CXCR7 expression (B).

Table 1. Biomarkers’ co-expression based on CXCR4, CXCL12, CXCR7 IHC staining.

| CXCL12 | Biomarker CXCR4 | CXCR7 | Epithelial Cells N (%) | Stromal Cells N (%) |
|--------|-----------------|-------|------------------------|---------------------|
| +      | +               | +     | 174 (56.5)             | 22 (7.1)            |
| +      | +               | -     | 19 (6.2)               | 2 (0.6)             |
| +      | -               | +     | 5 (1.6)                | 10 (3.2)            |
| -      | +               | +     | 57 (18.5)              | 125 (40.6)          |
| +      | -               | -     | 5 (1.6)                | 1 (0.3)             |
| -      | +               | -     | 27 (8.8)               | 57 (18.5)           |
| -      | -               | +     | 7 (2.3)                | 45 (14.6)           |
| -      | -               | -     | 14 (4.5)               | 6 (1.9)             |

3.3. Prognostic Meaning for CXCR4-CXCL12-CXCR7 in Advanced EOC

Out of 308 patients analyzed, 221 (72%) progressed and 102 (33%) died. In the univariate survival analysis considering continuous biomarkers, no significant associations were detected for PFS and OS (Supplementary Materials, Table S3). In univariate analysis considering the biomarkers’ cut-off, high epithelial CXCL12 appeared to be negatively associated with PFS (HR 1.39, 95%CI 1.06–1.81, \( p = 0.016 \)) and OS (HR 1.64, 95%CI 1.11–2.42, \( p = 0.014 \)); no associations were found for CXCR7 and CXCR4 and PFS or OS (Table 2).

The Kaplan–Meier curves for CXCL12 on PFS are shown in Figure 3A. However, using the shrinkage procedure with bootstrap confidence intervals, in order to adjust for overfitting due to best cut-off multiplicity testing, no biomarker was significantly associated with either PFS or OS (Table 2). Similar results were found in multivariate analysis considering both best and continuous biomarkers (Supplementary Materials,
Tables S4 and S5). A significant interaction was found in the PFS analysis between epithelial CXCL12 and FIGO stage, the former being associated with worse PFS among stage III patients but not within the smaller stage IV subgroup, with a p value for interaction of 0.044 (Figure 3B). An analysis of the interaction of the CXCR7 and CXCR4 best cut-off values for PFS with the main variables is shown in the Supplementary Materials, Figures S3 and S4.

Moreover, CXCR4, CXCL12 and CXCR7 expression was evaluated according to treatment response in 194 patients (63% of the study population) who represented the patients with measurable residual disease. Interestingly, higher epithelial CXCR4 expression was revealed in responders to treatment with carboplatin-paclitaxel and bevacizumab (Supplementary Materials, Table S6).
Table 2. Univariate analysis of biomarkers best cut-off for PFS and OS, original and shrunken coefficients.

|                               | Progression Free Survival | Overall Survival |
|-------------------------------|---------------------------|------------------|
|                               | Original Coefficient     | Shrunken Coefficients | Original Coefficient | Shrunken Coefficients |
|                               | HR CI(95%) P              |                  | HR CI(95%) P          |                  |
| CXCR7 Epithelial >36.7        | 0.79 (0.6–1.04) 0.093     | 0.86 (0.4–1.85) 0.695 | 0.84 (0.56–1.28) 0.423 | 1.10 (0.19–6.21) 0.916 |
| CXCR7 Stromal >20.0           | 1.16 (0.88–1.54) 0.297    | 1.01 (0.49–2.09) 0.974 | 1.23 (0.81–1.86) 0.335 | 0.98 (0.2–4.9) 0.985 |
| CXCL12 Epithelial >21.7       | 1.39 (1.06–1.81) 0.016    | 1.31 (0.67–2.58) 0.430 | 1.64 (1.11–2.42) 0.014 | 1.51 (0.66–3.48) 0.334 |
| CXCL12 Stromal >6.7           | 0.67 (0.4–1.11) 0.117     | 0.79 (0.4–1.56) 0.490 | 0.54 (0.24–1.24) 0.149 | 0.73 (0.12–4.47) 0.732 |
| CXCR4 Epithelial >130.0       | 0.69 (0.43–1.08) 0.106    | 0.79 (0.34–1.83) 0.585 | 0.56 (0.27–1.18) 0.130 | 0.72 (0.13–4.02) 0.710 |
| CXCR4 Stromal >65.0           | 0.77 (0.51–1.16) 0.209    | 0.91 (0.42–1.96) 0.807 | 0.68 (0.37–1.24) 0.210 | 0.87 (0.21–3.68) 0.849 |

4. Discussion

Genomic and molecular characterization of ovarian cancer allows a correct therapeutic approach. To characterize the tumor/tumor microenvironment, CXCR4-CXCL12-CXCR7 were evaluated in the epithelial and stromal compartment of 308 advanced EOC patients enrolled in the MITO16A/MaNGO-OV2 trial [25,27]. The entire CXCR4-CXCL12-CXCR7 axis was independently overexpressed in ovarian epithelial cancer tissue as compared to stroma. Stromal CXCR7 and CXCL12, although expressed in a minimal percentage of patients, were significantly lower in stage IV as compared to stage III patients. The evidence that indicates low stromal CXCL12 may favor metastases was previously described in breast cancer [30]. In terms of prognosis, epithelial CXCL12 correlated with PFS and OS although the significance was lost after the shrunken bootstrap analysis cross-validation was applied to avoid cut-offs overfitting. To the best of our knowledge, among several studies [22,31,32] describing the crucial role of the CXCR4-CXCL12 axis in ovarian cancer, this is the first prospective study in which the entire axis CXCR4-CXCL12-CXCR7 has been systematically evaluated in epithelial and stromal components, in a representative (n = 308) population of accurately selected stage III-IV ovarian cancer patients with adequate statistical analysis. However, the evaluated cohort of patients, which was comprised of FIGO IIIB-C and IV stage patients, might not be ideal for identifying prognostic factors as the early stages of disease are missing. Our findings suggest that high CXCR4 at diagnosis might identify, within the category of patients with poor prognosis ovarian cancer (R > 0), patients that could benefit from bevacizumab treatment [19]. Further studies are ongoing to better categorize the angiogenetic pathway expression in the study population.

Although the intent of the MITO16A/MaNGO-OV2 trial was “to explore the clinical and biological prognostic factors for advanced ovarian cancer patients receiving first-line treatment with carboplatin, paclitaxel, and bevacizumab”, data on the feasibility of interval debulking surgery (IDS) after carboplatin–paclitaxel–bevacizumab [33] and in the absence of relevant thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab [34] were also reported. Recently, the first molecular results of the biomarkers’ evaluation in MITO16A/MaNGO-OV2 patients was reported. Seven angiogenesis-related proteins and twelve microRNAs’ angiosignatures were evaluated, demonstrating that high miR-484, a VEGFB-targeting miRNA, was associated with longer progression-free and overall survival although the shrinkage procedure
to adjust for over-fitting hazard ratio estimates reduced the association significance [35]. Previous retrospective studies have reported the prognostic value of CXCL12 in 289 ovarian cancer patient as evaluated through tissue microarray [22], while a small study (44 EOC with a median 37 months follow-up) showed no prognostic meaning for CXCL12 [10]. Due to the low number of tumor infiltrating lymphocytes (TIL) and low PD-L1, ovarian cancer TME is classified as “cold”, although the tumor mutational burden is relatively high [35]. Nevertheless, TME varies according to the histological subtypes as the majority of HGSO (83%) present CD8 + TILs, while low-grade serous and endometrioid carcinoma had lower TILs and intra-epithelial CD8 + T cells associated with prolonged survival [36]. Neoadjuvant chemotherapy also affects TME through higher cytolysis activity, natural killer (NK) infiltration and the expansion of T cells [37], conversely increasing expression of the immune checkpoints PD1, PD-L1 and CTLA-4 [38]. In ovarian cancer TME, CXCL12 is secreted by several cells [39,40] and drives Tregs recruitment, inhibits leukocytes and facilitates M2 macrophage polarization, driving the TME toward an immunosuppressive status [41]. Interestingly, the most immunosuppressive CAF-S1 in EOC is rich in CXCL12 (CXCL12β) [42]. CXCL12–CAF induced EMT through the CXCR4/Wnt/β-catenin pathway, promoting cell proliferation and cisplatin resistance. Stromal CXCL12 is an independent prognostic marker of platinum sensitivity [43].

Based on the role played by CXCL12 in the EOC epithelia and stroma, targeting the CXCR4-CXCL12 axis has been coupled with immune checkpoint inhibitors antibodies, as the efficacy of single-agent immune-checkpoint blockade in EOC is limited [44]. The CXCR4 antagonist, AMD3100 and anti-PD-1 significantly enhanced antitumor effects by potentiating effector T-cell infiltration, function and increasing memory T cells in “in vivo” models. AMD3100 promoted a reduction in intra-tumoral Tregs and the conversion of Treg cells into T-helpers [41]. In a syngeneic ovarian cancer model, locoregional delivery of the oncolytic vaccinia virus (OVV)-plus CXCR4 antagonist (CXCR4-A) reduced the tumor load and promoted the immune response through CD103 + dendritic cells [45]. Thus, we can speculate that EOC patients might benefit from CXCL12 axis blockade in combination with chemotherapy, immunotherapy and molecular therapies targeting macrophages, Tregs and fibroblasts [35].

5. Conclusions

Our findings shed light on the key role of CXCL12, CXCR7 and CXCR4 in EOC. In univariate analysis, high epithelial CXCL12 appeared to be negatively associated with PFS and OS, although after adjusting for overfitting the significance was lost. A significant interaction was detected in the PFS analysis between epithelial CXCL12 and FIGO III stage patients. Thus, although no prognostic factors were identified through objective and rigorous statistical methods with ovarian cancer clinical data, the data support the rationale for CXCL12 targeting therapy in EOC management.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers14071849/s1. Figure S1. Flow chart of inclusion and exclusion criteria, Figure S2. Correlation tested by Kendall test modified for zero inflated Wilcoxon rank test (ZIWT) for zero-inflated data with permutations (except for Residual Disease where Kruskal-Wallis zero inflated (ZIKW) was applied), Figure S3. Forest plot of hazard ratios (HR) of progression, and 95% CI, evaluated in different subgroups (Cox proportional hazards model analysis) and interaction comparison between prognostic factor and CXCR7 in epithelial and stromal cells, Figure S4. Forest plot of hazard ratios (HR) of progression and 95% CI, evaluated in different subgroups (Cox proportional hazards model analysis) and interaction comparison between prognostic factor and CXCR4 in epithelial and stromal cells, Table S1. Patients characteristics in translational analysis, Table S2. Multivariable analysis of clinical prognostic factors for PFS and OS, Table S3. Univariate analysis of biomarkers (continuous and dummy for zero variables) for PFS and OS, Table S4. Analysis of biomarkers best cut-off adjusted for clinical characteristics for PFS and OS using Shrunken coefficients, Table S5. Analysis of biomarkers (continuous and dummy for zero variables) adjusted for clinical
characteristics for PFS and OS. Table S6. CXCR4, CXCL12 and CXCR7 expression and Response to treatment.

**Author Contributions:** Conception and design of the work: D.C., S.P. and S.S. (Stefania Scala); acquisition, analysis and interpretation of data for the work: C.D., A.S., L.A., P.C., V.S., S.S. (Simona Signoriello), N.S.L., R.D.C., G.S., D.R., V.T. and F.P.; drafting the work and revising it critically for important intellectual content: C.D., A.S., F.P., M.N., F.G., L.P., F.R., D.L., C.P., N.C., G.F.Z., M.C.P., P.G., S.P. and S.S. (Stefania Scala). All authors have read and agreed to the published version of the manuscript.

**Funding:** Funding: This research was partly supported by the Italian Association for Cancer Research (AIRC) IG 2016 (ID 18921) and by Roche to S.P.; Ricerca Corrente grant M2/7 from Ministero della Salute to D.C.

**Institutional Review Board Statement:** MITO16A/MaNGO-OV2 is a phase IV registered trial (EudraCT number: 2012-003043-29) that aims to explore the prognostic role of selected biomarkers in EOC patients treated with first-line chemotherapy (paclitaxel + carboplatin × 6) plus BEV (15 mg/kg) for 15 months. The study has been approved by the Ethics Committee (first approval by the Ethics Committee of the proponent institute, INT Pascale Napoli, Prot. #383/12 of 19 July 2012) and all patients provided written informed consent. In 2015, all research groups were invited by the MITO Coordinator to review their applications according to new data generated by their labs and/or updated literature and to check whether the proposed biomarkers could be considered appropriate and/or whether new biomarkers should be added. This review process highlighted the need to modify and integrate the list of proposed biomarkers approved by the Ethic Committee in 2016.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Acknowledgments:** We are grateful to the patients who consented to donating their tumor samples. Vittorio Simeon was supported by the Programma VALERE, University of Campania “Luigi Vanvitelli”.

**Conflicts of Interest:** Perrone reports grants, personal fees and non-financial support from Bayer, personal fees from Sandoz, grants and personal fees from Incyte, personal fees from Celgene, grants and personal fees from AstraZeneca, personal fees from Pierre Fabre, personal fees from Janssen Cilag, grants from Roche, grants from Pfizer, outside the submitted work. The MITO16A/MaNGO-OV2 is a multicenter national, academic trial sponsored by NCI Naples. Roche Italy provided bevacizumab and partial funding for trial activities and for the translational project. AIRC (Associazione Italiana per la Ricerca sul Cancro) supported translational studies with the IG 5776. AIOM (Associazione Italiana di Oncologia Medica) supported biomarker analysis with a grant. Roche, AIRC and AIOM did not play any role in the study design, protocol writing, data collection, data analysis and interpretation, and manuscript writing.

**References**

1. Arend, R.; Martinez, A.; Szul, T.; Birrer, M.J. Biomarkers in ovarian cancer: To be or not to be. *Cancer* **2019**, *125* (Suppl. S24), 4563–4572. [CrossRef] [PubMed]
2. Gaitskell, K.; Green, J.; Pirie, K.; Barnes, I.; Hermon, C.; Reeves, G.K.; Beral, V. Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study. *Int. J. Cancer* **2018**, *142*, 281–289. [CrossRef] [PubMed]
3. Trope, C.; Kaern, J. Adjuvant Chemotherapy for Early-Stage Ovarian Cancer: Review of the Literature. *J. Clin. Oncol.* **2007**, *25*, 2909–2920. [CrossRef] [PubMed]
4. Bast, R.C., Jr.; Hennessy, B.; Mills, G.B. The biology of ovarian cancer: New opportunities for translation. *Nat. Rev. Cancer* **2009**, *9*, 415–428. [CrossRef] [PubMed]
5. Colombo, N.; Sessa, C.; du Bois, A.; Ledermann, J.; McCluggage, W.G.; McNeish, I.; Morice, P.; Pignata, S.; Ray-Coquard, I.; Vergote, I.; et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease zag. *Ann. Oncol.* **2019**, *30*, 672–705. [CrossRef]
6. Ledermann, J.A.; Raja, F.A.; Fotopoulou, C.; Gonzalez-Martin, A.; Colombo, N.; Sessa, C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **2013**, *24*, vi24–vi32. [CrossRef]
7. Moore, K.; Colombo, N.; Scambia, G.; Kim, B.G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G.S.; et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N. Engl. J. Med.* **2018**, *379*, 2495–2505. [CrossRef]
8. Poveda, A.; Floquet, A.; Ledermann, J.A.; Asher, R.; Pensom, R.T.; Oza, A.M.; Korach, J.; Huzarski, T.; Pignata, S.; Friedlander, M.; et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2021, 22, 620–631. [CrossRef]

9. Buys, S.S.; Partridge, E.; Black, A.; Johnson, C.C.; Lamerato, L.; Isaacs, C.; Reding, D.J.; Greenlee, R.T.; Yokochi, L.A.; Kessel, B.; et al. Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. *JAMA* 2011, 305, 2295–2303. [CrossRef]

10. Jiang, Y.P.; Wu, X.H.; Shi, B.; Wu, W.X.; Yin, G.R. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: An independent prognostic factor for tumor progression. *Gynecol. Oncol.* 2006, 103, 226–233. [CrossRef]

11. Mao, T.L.; Fan, K.F.; Liu, C.L. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer. *Gene Ther. 2018*, 17, 532–543. [CrossRef] [PubMed]

12. Figueras, A.; Alsinas-Sanchis, E.; Lahiguera, A.; Abreu, M.; Muinelo-Romay, L.; Moreno-Bueno, G.; Casanovas, O.; Graupera, M.; Matsias-Guiu, X.; Vidal, A.; et al. A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination. *Mol. Cancer Ther.* 2018, 17, 532–543. [CrossRef] [PubMed]

13. Turut, F.A.; Acidereli, H.; Cevik, O. Suppression of MicroRNA-144 Promotes CXCR4 and CXCL12 Expression and Downregulates Apoptosis in Ovarian Cancer Cells. *bioRxiv* 2020, bioRxiv2020.2004.2017.042382. [CrossRef] [PubMed]

14. De Clercq, E. Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration. *Anticor. Chem. Chemother.* 2019, 27, 204020619829382. [CrossRef] [PubMed]

15. Xue, J.; Li, R.; Gao, D.; Chen, F.; Xie, H. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System against Ovarian Cancer. *Int. J. Nanomed.* 2020, 15, 5701–5718. [CrossRef]

16. Zheng, N.; Liu, W.; Chen, J.; Li, B.; Liu, Ji; Wang, J.; Gao, Y.; Shao, J.; Jia, L. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer. *Mol. Carcinog.* 2019, 58, 144–155. [CrossRef] [PubMed]

17. Zhang, J.; Quan, L.-N.; Meng, Q.; Wang, H.-Y.; Wang, Ji; Yu, P.; Fu, J.-T.; Li, Y.-J.; Chen, J.; Cheng, H.; et al. miR-548e Sponged by ZFAS1 Regulates Metastasis and Cisplatin Resistance of OC by Targeting CXCR4 and let-7a/BCL-XL/S Signaling Axis. *Mol. Ther.-Nucleic Acids* 2020, 20, 621–638. [CrossRef]

18. Scotton, C.J.; Wilson, J.L.; Milliken, D.; Stamp, G.; Balkwill, F.R. Epithelial Cancer Cell Migration. *Cancer Res.* 2021, 81, 4961.

19. Kryczek, I.; Lange, A.; Mottram, P.; Alvarez, X.; Cheng, P.; Hogan, M.; Moons, L.; Wei, S.; Zou, L.; Machelon, V.; et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. *Cancer Res.* 2020, 85, 465–472.

20. Wang, F.Q.; So, J.; Reierstad, S.; Fishman, D.A. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. *Int. J. Cancer 2006*, 118, 879–888. [CrossRef]

21. Kajiyama, H.; Shibata, K.; Terauchi, M.; Ino, K.; Nawa, A.; Kikkawa, F. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. *Int. J. Cancer 2008*, 122, 91–99. [CrossRef] [PubMed]

22. Popple, A.; Durrant, L.G.; Spendlove, I.; Rolland, P.; Scott, I.V.; Deen, S.; Ramage, J.M. The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer. *Br. J. Cancer* 2012, 106, 1306–1313. [CrossRef] [PubMed]

23. Balabanian, K.; Lagane, B.; Infantino, S.; Chow, K.Y.; Harrigué, J.; Moepps, B.; Arenzana-Seisdedos, F.; Thelen, M.; Bacherlfe, F. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. *J. Biol. Chem. 2005*, 280, 35760–35767. [CrossRef]

24. Furuya, M.; Suyama, T.; Usui, H.; Kasuya, Y.; Nishiyama, M.; Tanaka, N.; Ishiwata, I.; Nagai, Y.; Shouz, M.; Kimura, S. Up-regulation of CX chemokines and their receptors: Implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. *Hum. Pathol.* 2007, 38, 1676–1687. [CrossRef] [PubMed]

25. Daniele, G.; Raspagliesi, F.; Scambia, G.; Pisano, C.; Colombo, N.; Frezzini, S.; Tognon, G.; Artioli, G.; Gadducci, A.; Lauria, R.; et al. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: The phase IV MITO-16A/MaNGO-OV2A study. *Int. J. Gynecol. Cancer.* 2021, 31, 875–882. [CrossRef]

26. Calzolari, A.; Napolitano, M.; Bravo, E. Review of the Italian current legislation on research biobanking activities on the eve of the participation of national biobanks’ network in the legal consortium BMBRI-ERIC. *Biopreserv. Biobank.* 2013, 11, 124–128. [CrossRef]

27. Califano, D.; Russo, D.; Scognamiglio, G.; Loris, S.N.; Spina, A.; Bello, M.A.; Capilungo, A.; Galdiero, F.; De Cecio, R.; Bevilacqua, S.; et al. Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience. *Cells 2020*, 9, 903. [CrossRef] [PubMed]

28. Pimentel, R.S.; Niewiadomska-Bugaj, M.; Wang, J.C. Association of zero-inflated continuous variables. *Stat. Probab. Lett.* 2015, 96, 61–67. [CrossRef]

29. Holländer, N.; Sauerbrei, W.; Schumacher, M. Confidence intervals for the effect of a prognostic factor after selection of an ‘optimal’ cutpoint. *Stat. Med.* 2004, 23, 1701–1713. [CrossRef]

30. Yu, P.F.; Huang, Y.; Xu, C.L.; Lin, L.Y.; Han, Y.Y.; Sun, W.H.; Hu, G.H.; Rabson, A.B.; Wang, Y.; Shi, Y.F. Downregulation of CXCL12 in mesenchymal stromal cells by TGFß promotes breast cancer metastasis. * Oncogene 2017*, 36, 840–849. [CrossRef]

31. Machelon, V.; Gaudin, F.; Camilleri-Broët, S.; Nasreddine, S.; Bouchet-Delbos, L.; Pujade-Lauraine, E.; Alexandre, J.; Gladieff, L.; Arenzana-Seisdedos, F.; Emile, D.; et al. CXCL12 expression by healthy and malignant ovarian epithelial cells. *BMC Cancer 2011*, 11, 97. [CrossRef] [PubMed]
32. Pils, D.; Pinter, A.; Reibenwein, J.; Alfanz, A.; Horak, P.; Schmid, B.C.; Heiﬂer, L.; Horvat, R.; Reinthaller, A.; Zeillinger, R.; et al. In ovarian cancer the prognostic inﬂuence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. Br. J. Cancer 2007, 96, 485–491. [CrossRef] [PubMed]

33. Daniele, G.; Lorusso, D.; Scambia, G.; Cecere, S.C.; Nicoletto, M.O.; Breda, E.; Colombo, N.; Artioli, G.; Cannella, L.; Lo Re, G.; et al. Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-Paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. Gynecol. Oncol. 2017, 144, 256–299. [CrossRef] [PubMed]

34. Di Liello, R.; Arenare, L.; Raspagliesi, F.; Scambia, G.; Pisano, C.; Colombo, N.; Frezzini, S.; Tognon, G.; Artioli, G.; Gadducci, A.; et al. Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: Secondary analysis of the phase IV Mito 16A/MaNGO-OV2A trial. Int. J. Gynecol. Cancer 2021, 31, 1348. [CrossRef] [PubMed]

35. Califano, D.; Gallo, D.; Rampioni Vinciguerra, G.L.; De Cecio, R.; Arenare, L.; Signoriello, S.; Russo, D.; Ferrandina, G.; Citron, F.; Losito, N.S.; et al. Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV Mito16A/MaNGO OV-2 Translational Study. Cancers 2022, 14, 1849. [CrossRef]

36. Ovarian Tumor Tissue Analysis (OTTA) Consortium; Goode, E.L.; Block, M.S.; Kalli, K.R.; Vierkant, R.A.; Chen, W.; Fogarty, Z.C.; Gentry-Maharaj, A.; Tołoczko, A.; Hein, A.; et al. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol. 2017, 3, e173290. [CrossRef]

37. Jiménez-Sánchez, A.; Cybulska, P.; Mager, K.L.; Koplev, S.; Cast, O.; Couturier, D.-L.; Memon, D.; Selenica, P.; Nikolovski, I.; Mazaheri, Y.; et al. Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nat. Genet. 2020, 52, 582–593. [CrossRef]

38. Friese, C.; Harbst, K.; Borch, T.H.; Westergaard, M.C.W.; Pedersen, M.; Kverneland, A.; Jönsson, G.; Donia, M.; Svane, I.M.; Met, Ö. CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-inﬁltrating lymphocytes in ovarian cancer. Sci. Rep. 2020, 10, 3914. [CrossRef]

39. Zhang, F.; Cui, J.-Y.; Gao, H.-F.; Yu, H.; Gao, F.-F.; Chen, J.-L.; Chen, L. Cancer-associated fibroblasts induce epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer via CXCL12/CXCR4 axis. Future Oncol. 2020, 16, 2619–2633. [CrossRef] [PubMed]

40. Ribas, A.; Wolchok, J.D. Cancer immunotherapy using checkpoint blockade. Science 2018, 359, 1350–1355. [CrossRef] [PubMed]